News | May 08, 2022
Quality issues force Novartis to suspend production of radioligand therapy medicines
The production suspension impacts commercial and clinical trial supply
The production suspension impacts commercial and clinical trial supply
Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities
Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications
PharmaLogic will assist ARTBIO with radiochemistry and supply of the finished radiopharmaceutical product for future Phase I and II clinical trials of AB001 from their facility in New York
Pluvicto and Scemblix launches are progressing well and we are awaiting data in earlier lines of therapy.
Transformation to pure-play Innovative Medicines company nears completion
USFDA also approved complementary diagnostic imaging agent, Locametz, after radiolabeling with gallium-68 for the identification of PSMA-positive lesions
Focused medicines company delivering strong operational performance. Building depth in five core therapeutic areas, strength in technology platforms, and a balanced geographic footprint
Subscribe To Our Newsletter & Stay Updated
